Efficacy of Pollexia Administration for Infertile
Males Associated with Asymptomatic Pyospermia

Tetsuya Arai, Shin Horiuchi, Kenichiro Yoshida
Department of Urology, Dokkyo University School of Medicine


The cases, that white blood cell is significantly higher in semen, accounts for 16 ~ 17% of male infertility patients. Interestingly, it was common that no bacterial finding is presented in these cases, using standardized bacterial test, PCR methods for Chlamydia trachomatis (C. trachomatis), and semi-quantitative analysis for Urea plasma urealyticum (U. urealyticum). Although these cases are classified in nonbacterial chronic prostatitis, it has been generally recognized to be associated with male infertility. In present study, we reported that administration of Pollexia reduce PMN-elastase activity and to improve seminal findings in semen for 17 male infertility patients with no bacterial finding in semen.

Materials and Methods

17 male infertility patients associated with nonbacterial asymptomatic pyospermia were treated with Pollexia 6 tablets daily over 12 weeks, then sperm density, progressively motile sperm ratio, sperm motility and PMN-elastase activity in semen were measured.


In all patients, progressively motile sperm ratio, sperm motility and PMN-elastase activity in seminal fluid were improved.


Administration of Pollexia is seemed to be effective in the treatment of infertile males associated with nonbacterial asymptomatic pyospermia.

Statements herein have not been reviewed by the Food and Drug Administration
Not intended to treat, cure, prevent or diagnose any disease

has been shown to help alleviate the following symptoms:

Excessive urges to urinate, including during the night.

Pain associated with prostate inflammation or enlargement.

Blood in urine.

Lack of seminal fluid production.

Copyright 2013 VIXOVA®